![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 25, 2017 2:21:30 PM
I know when I bought around .50 they did not have one clinical trial. Just pre clinical data for Kevetrin and pre clinical data for Prurisol.
I think it was in the 90's million shares OS? Can't remember though.
Now:125 million OS
They own the entire B franchise. Dominated a phase 2b B-Absssi trial that matched Daptomycin which is a billion dollar drug. And B has several huge benefits in comparison.
Started a B-OM phase 2 trial for head/neck cancer patients
Started a B-Up phase 2 PoC trial that is showing wonderful progress and feedback/results.
Signed an agreement having a major Pharm test B on implants and devices to limit infections. That Pharm ordered a second huge batch of B
Kevetrin successfully completed a phase 1 trial that took 3 plus years and we never reached an MTD. Very safe unlike any other p53 drug.
About to start phase 2 trial w K on ovarian cancer
They have tested and continue to develop an ORAL K. All tests look great thus far.
Received how many FDA designations? I lost count. Even one that recently was sold for hundreds of millions. At lunch so I can't remember what designation that is called.
Prurisol was granted 505(b) and completed a phase 1 cross over study.
Completed a PoC phase 2 trial with P showing excellent data at the 200 mg level. Very comparable to Otezla
Now started a phase 2b POWERED study at 25 sites.
My finger is tired. But for the amount of what CTIX has been able to accomplish while diluting very little!!!!! I mean I'd expect to see 5-10 dollars a share.
Stay long and stay strong.
Go CTIX.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM